Eladur

In a report issued Tuesday, Cantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and $3.00 price target on shares of DURECT Corporation (NASDAQ: DRRX), a micro-cap specialty pharmaceutical company. The firm likes the company in account of its “attractive post-operative...